CT45A7
associated omics dataQ-omics provides the consensus-scored CT45A7 profile across patient tissues and cancer cell-line models. CT45A7 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in OV.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT45A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes CT45A7 survival associations across molecular data types. CT45A7 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT45A7 RNA expression–survival associations across cancer types. High CT45A7 expression shows unfavorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for CT45A7 RNA expression.
Cross-omics associations
This table shows molecular features associated with CT45A7 in patient tissues and cancer cell lines. In cancer cell lines, CT45A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.